FLT3 and acute myeloid leukemia: The maintenance of sorafenib therapy after allo-HSCT could further decrease the incidence of relapse and improve LFS[40,41] of AML patients with FLT3 mutation; however, Xuan et al. [40] reported that male patients who were MRD positivity before or after allo-HSCT could benefit from sorafenib maintenance therapy.